If you made any changes in Pure these will be visible here soon.

Research Output 1998 2019

2014
14 Citations (Scopus)

Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement

Fujiwara, A., Higashiyama, M., Kanou, T., Tokunaga, T., Okami, J., Kodama, K., Nishino, K., Tomita, Y. & Okamoto, I., Feb 1 2014, In : Lung Cancer. 83, 2, p. 302-304 3 p.

Research output: Contribution to journalArticle

Gene Rearrangement
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Fluorescence In Situ Hybridization
anaplastic lymphoma kinase
53 Citations (Scopus)

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

Park, K. S., Raffeld, M., Moon, Y. W., Xi, L., Bianco, C., Pham, T., Lee, L. C., Mitsudomi, T., Yatabe, Y., Okamoto, I., Subramaniam, D., Mok, T., Rosell, R., Luo, J., Salomon, D. S., Wang, Y. & Giaccone, G., Jul 1 2014, In : Journal of Clinical Investigation. 124, 7, p. 3003-3015 13 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
MicroRNAs
Epithelial-Mesenchymal Transition
Protein-Tyrosine Kinases
Mutation
3 Citations (Scopus)

Current status and future perspectives of cooperative study groups for lung cancer in Japan

Kawano, Y., Okamoto, I., Fukuda, H., Ohe, Y., Nakamura, S., Nakagawa, K., Hotta, K., Kiura, K., Takiguchi, Y., Saka, H., Okamoto, H., Takayama, K., Semba, H., Kobayashi, K., Kenmotsu, H., Tsuboi, M., Yamamoto, N., Nukiwa, T. & Nakanishi, Y., Nov 1 2014, In : Respiratory Investigation. 52, 6, p. 339-347 9 p.

Research output: Contribution to journalReview article

Lung Neoplasms
Japan
Clinical Trials
Research Personnel
Therapeutics
18 Citations (Scopus)

Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement

Hayashi, H., Okamoto, I., Tanizaki, J., Tanaka, K., Okuda, T., Kato, A., Nishimura, Y. & Nakagawa, K., Jan 1 2014, In : Journal of Clinical Oncology. 32, 36, p. e122-e124 A31.

Research output: Contribution to journalArticle

Gene Rearrangement
Receptor Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Cysts
29 Citations (Scopus)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Iwama, E., Okamoto, I., Harada, T., Takayama, K. & Nakanishi, Y., Mar 5 2014, In : OncoTargets and Therapy. 7, p. 375-385 11 p.

Research output: Contribution to journalReview article

Lung Neoplasms
Non-Small Cell Lung Carcinoma
anaplastic lymphoma kinase
United States Food and Drug Administration
Oncogenes
352 Citations (Scopus)

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study

Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., Nagase, S., Okamoto, I., Yamanaka, T., Tajima, K., Harada, R., Fukuoka, M. & Yamamoto, N., Oct 1 2014, In : The Lancet Oncology. 15, 11, p. 1236-1244 9 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Mutation
Therapeutics
Disease-Free Survival
Bevacizumab
18 Citations (Scopus)

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study

Okamoto, I., Sakai, K., Morita, S., Yoshioka, H., Kaneda, H., Takeda, K., Hirashima, T., Kogure, Y., Kimura, T., Takahashi, T., Atagi, S., Seto, T., Sawa, T., Yamamoto, M., Satouchi, M., Okuno, M., Nagase, S., Takayama, K., Tomii, K., Maeda, T. & 8 others, Oizumi, S., Fujii, S., Akashi, Y., Nishino, K., Ebi, N., Nakagawa, K., Nakanishi, Y. & Nishio, K., Jan 1 2014, In : Oncotarget. 5, 8, p. 2293-2304 12 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Japan
Mutation
19 Citations (Scopus)

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer

Hirsh, V., Okamoto, I., Hon, J. K., Page, R. D., Orsini, J., Sakai, H., Zhang, H., Renschler, M. F. & Socinski, M. A., Jan 1 2014, In : Journal of Thoracic Oncology. 9, 1, p. 83-90 8 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Peripheral Nervous System Diseases
Physicians
3 Citations (Scopus)

Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer

Naito, T., Seto, T., Takeda, K., Goto, K., Okamoto, I., Nakagawa, K., Oba, T., Murakami, H., Takahashi, T., Yamanaka, T. & Yamamoto, N., Dec 1 2014, In : Lung Cancer. 86, 3, p. 339-343 5 p.

Research output: Contribution to journalArticle

Phase II Clinical Trials
Leucovorin
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Pneumatosis Cystoides Intestinalis
13 Citations (Scopus)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group

Murakami, H., Yamanaka, T., Seto, T., Sugio, K., Okamoto, I., Sawa, T., Hirashima, T., Takeda, K., Atagi, S., Fukuoka, M., Nakanishi, Y., Nakagawa, K. & Yamamoto, N., Jan 1 2014, In : Cancer Science. 105, 8, p. 989-995 7 p.

Research output: Contribution to journalArticle

zoledronic acid
docetaxel
Non-Small Cell Lung Carcinoma
Japan
Confidence Intervals
33 Citations (Scopus)
erbB-1 Genes
Non-Small Cell Lung Carcinoma
Mutation
Survival
Protein-Tyrosine Kinases
42 Citations (Scopus)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

Kawakami, H., Okamoto, I., Yonesaka, K., Okamoto, K., Shibata, K., Shinkai, Y., Sakamoto, H., Kitano, M., Tamura, T., Nishio, K. & Nakagawa, K., Jan 1 2014, In : Oncotarget. 5, 23, p. 11847-11856 10 p.

Research output: Contribution to journalArticle

Neuregulin-1
Anti-Idiotypic Antibodies
Colorectal Neoplasms
Phosphorylation
Cetuximab
69 Citations (Scopus)

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer

Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J., Rawal, B., Fisher, K. J., Chen, A. Y., Kitano, M., Morita, Y., Yamaguchi, H., Shibata, K., Okabe, T., Okamoto, I., Nakagawa, K. & Haura, E. B., Aug 1 2014, In : Clinical Cancer Research. 20, 15, p. 4059-4074 16 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Tyrosine
src-Family Kinases
Phosphorylation
2013
14 Citations (Scopus)

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

Okamoto, W., Yoshino, T., Takahashi, T., Okamoto, I., Ueda, S., Tsuya, A., Boku, N., Nishio, K., Fukuoka, M., Yamamoto, N. & Nakagawa, K., Nov 1 2013, In : Cancer chemotherapy and pharmacology. 72, 5, p. 1063-1071 9 p.

Research output: Contribution to journalArticle

Pharmacodynamics
Pharmacokinetics
Epidermal Growth Factor Receptor
Toxicity
Tumors

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Tsuya, A., Kurata, T., Tamiya, A., Okamoto, I., Ueda, S., Sakai, D., Sugimoto, N., Matsumoto, K., Goto, I., Yamamoto, N., Fukuoka, M. & Nakagawa, K., Dec 1 2013, In : Investigational New Drugs. 31, 6, p. 1568-1572 5 p.

Research output: Contribution to journalArticle

Cisplatin
Carcinoma
Combination Drug Therapy
Appointments and Schedules
Febrile Neutropenia
1 Citation (Scopus)

A phase i study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Hasegawa, Y., Okamoto, I., Takezawa, K., Miyazaki, M., Tsurutani, J., Yonesaka, K., Morinaga, R., Tsuya, A., Terashima, M., Kudoh, T., Azuma, K., Kurata, T., Nishikawa, T., Fukuoka, M., Nishimura, Y. & Nakagawa, K., Jun 1 2013, In : Investigational New Drugs. 31, 3, p. 599-604 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
Stomatitis
Pneumonia
1 Citation (Scopus)

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer

Okamoto, K., Okamoto, I., Miyazaki, M., Tanaka, K., Kaneda, H. & Nakagawa, K., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1364-1366 3 p.

Research output: Contribution to journalArticle

Bronchoscopy
Non-Small Cell Lung Carcinoma
Hemorrhage
Lung
Hemoptysis
59 Citations (Scopus)
Lung Neoplasms
Central Nervous System
Radiotherapy
Non-Small Cell Lung Carcinoma
Disease Progression
12 Citations (Scopus)

Clinical response to crizotinib retreatment after acquisition of drug resistance

Matsuoka, H., Kurata, T., Okamoto, I., Kaneda, H., Tanaka, K. & Nakagawa, K., Jul 1 2013, In : Journal of Clinical Oncology. 31, 19

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Serine Endopeptidases
Neoplasm Drug Resistance
Drug Administration Schedule
Antineoplastic Combined Chemotherapy Protocols
37 Citations (Scopus)

Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study

Yoshioka, H., Okamoto, I., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Atagi, S., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Nakanishi, Y. & Nakagawa, K., May 1 2013, In : Annals of Oncology. 24, 5, p. 1326-1331 6 p., mds629.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Histology
Japan
Safety
26 Citations (Scopus)

Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer

Satouchi, M., Okamoto, I., Sakai, H., Yamamoto, N., Ichinose, Y., Ohmatsu, H., Nogami, N., Takeda, K., Mitsudomi, T., Kasahara, K. & Negoro, S., Jul 1 2013, In : Lung Cancer. 81, 1, p. 97-101 5 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Safety
Paclitaxel
Thrombocytopenia
1 Citation (Scopus)

Erratum: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (Investigational New Drugs (DOI 10.1007/s10637-013-9941-z))

Okamoto, I., Aoe, K., Kato, T., Hosomi, Y., Yokoyama, A., Imamura, F., Kiura, K., Hirashima, T., Nishio, M., Nogami, N., Okamoto, H., Saka, H., Yamamoto, N., Yoshizuka, N., Sekiguchi, R., Kiyosawa, K., Nakagawa, K. & Tamura, T., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1395-1396 2 p.

Research output: Contribution to journalComment/debate

Pemetrexed
Investigational Drugs
Carboplatin
Non-Small Cell Lung Carcinoma
Therapeutics
24 Citations (Scopus)

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of west Japan oncology group (WJOG) study 3906L

Kogure, Y., Ando, M., Saka, H., Chiba, Y., Yamamoto, N., Asami, K., Hirashima, T., Seto, T., Nagase, S., Otsuka, K., Yanagihara, K., Takeda, K., Okamoto, I., Aoki, T., Takayama, K., Yamasaki, M., Kudoh, S., Katakami, N., Miyazaki, M. & Nakagawa, K., Jan 1 2013, In : Journal of Thoracic Oncology. 8, 6, p. 753-758 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Histology
Japan
Smoking
Adenocarcinoma
18 Citations (Scopus)

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma

Kawakami, H., Okamoto, I., Terao, K., Sakai, K., Suzuki, M., Ueda, S., Tanaka, K., Kuwata, K., Morita, Y., Ono, K., Nishio, K., Nishimura, Y., Doi, K. & Nakagawa, K., Jan 1 2013, In : Cancer Medicine. 2, 6, p. 933-941 9 p.

Research output: Contribution to journalArticle

Squamous Cell Carcinoma
DNA
p16 Genes
Methylation
Cisplatin
64 Citations (Scopus)

MET amplification as a potential therapeutic target in gastric cancer

Kawakami, H., Okamoto, I., Arao, T., Okamoto, W., Matsumoto, K., Taniguchi, H., Kuwata, K., Yamaguchi, H., Nishio, K., Nakagawa, K. & Yamada, Y., Jan 1 2013, In : Oncotarget. 4, 1, p. 9-17 9 p.

Research output: Contribution to journalArticle

Stomach Neoplasms
Protein-Tyrosine Kinases
Therapeutics
Polymerase Chain Reaction
Gene Dosage
15 Citations (Scopus)

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Kaneda, H., Yoshida, T. & Okamoto, I., May 29 2013, In : Cancer Management and Research. 5, 1, p. 91-101 11 p.

Research output: Contribution to journalReview article

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
25 Citations (Scopus)

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Okamoto, I., Aoe, K., Kato, T., Hosomi, Y., Yokoyama, A., Imamura, F., Kiura, K., Hirashima, T., Nishio, M., Nogami, N., Okamoto, H., Saka, H., Yamamoto, N., Yoshizuka, N., Sekiguchi, R., Kiyosawa, K., Nakagawa, K. & Tamura, T., Jan 1 2013, In : Investigational New Drugs. 31, 5, p. 1275-1282 8 p.

Research output: Contribution to journalArticle

Pemetrexed
Carboplatin
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Therapeutics
29 Citations (Scopus)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Li, J., Bennett, K., Stukalov, A., Fang, B., Zhang, G., Yoshida, T., Okamoto, I., Kim, J. Y., Song, L., Bai, Y., Qian, X., Rawal, B., Schell, M., Grebien, F., Winter, G., Rix, U., Eschrich, S., Colinge, J., Koomen, J., Superti-Furga, G. & 1 others, Haura, E. B., Nov 5 2013, In : Molecular Systems Biology. 9, 705.

Research output: Contribution to journalArticle

Growth Factors
resistance mechanisms
Vulnerability
Epidermal Growth Factor Receptor
Receptor
8 Citations (Scopus)

Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer

Urata, Y., Okamoto, I., Takeda, M., Hattori, Y., Okuno, K., Shimada, T., Kurata, T., Kaneda, H., Miyazaki, M., Terashima, M., Tanaka, K., Morita, S., Nakagawa, K., Negoro, S. & Satouchi, M., Jun 15 2013, In : Cancer. 119, 12, p. 2275-2281 7 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Maintenance
Drug Therapy
Disease Progression
5 Citations (Scopus)

Phase i and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kiyota, H., Okamoto, I., Takeda, M., Daga, H., Naito, T., Miyazaki, M., Okada, H., Hayashi, H., Tanaka, K., Terashima, M., Azuma, K., Murakami, H., Takeda, K., Yamamoto, N. & Nakagawa, K., Apr 1 2013, In : Cancer Chemotherapy and Pharmacology. 71, 4, p. 859-865 7 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Therapeutics
Chemotherapy
Aspartate Aminotransferases
Disease-Free Survival
8 Citations (Scopus)

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Hayashi, H., Tsurutani, J., Satoh, T., Masuda, N., Okamoto, W., Morinaga, R., Terashima, M., Miyazaki, M., Okamoto, I., Nishida, Y., Tominaga, S., Tokunaga, Y., Yamaguchi, M., Sakamoto, J., Nakayama, T. & Nakagawa, K., Apr 1 2013, In : Breast Cancer. 20, 2, p. 131-136 6 p.

Research output: Contribution to journalArticle

irinotecan
Breast Neoplasms
Anthracyclines
Taxoids
Topoisomerase I Inhibitors
1 Citation (Scopus)

Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer

Hayashi, H., Okamoto, I., Ueda, S., Tanaka, K., Okamoto, K., Kawakami, H., Nishina, S., Takeda, M., Fujisaka, Y., Satoh, T., Terao, K., Nishimura, Y., Doi, K. & Nakagawa, K., Dec 1 2013, In : Anticancer research. 33, 12, p. 5699-5706 8 p.

Research output: Contribution to journalArticle

Head and Neck Neoplasms
Pharmacokinetics
Neutropenia
Endpoint Determination
nedaplatin
12 Citations (Scopus)

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

Kawakami, H., Okamoto, I., Hayashi, H., Taguri, M., Morita, S. & Nakagawa, K., Sep 1 2013, In : European Journal of Cancer. 49, 14, p. 3003-3009 7 p.

Research output: Contribution to journalArticle

Stomach Neoplasms
Drug Therapy
Survival
Disease-Free Survival
19 Citations (Scopus)

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy

Hayashi, H., Okamoto, I., Taguri, M., Morita, S. & Nakagawa, K., Jul 15 2013, In : Clinical Lung Cancer. 14, 3, p. 261-266 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Disease-Free Survival
Therapeutics
232 Citations (Scopus)

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial

Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., Hamamoto, Y., Morita, S., Okamoto, I., Boku, N. & Hyodo, I., Dec 10 2013, In : Journal of Clinical Oncology. 31, 35, p. 4438-4444 7 p.

Research output: Contribution to journalArticle

irinotecan
Paclitaxel
Combination Drug Therapy
Platinum
Stomach Neoplasms
42 Citations (Scopus)
Pyrazoles
Pyridines
Bone Neoplasms
X Ray Computed Tomography
Gene Rearrangement
48 Citations (Scopus)

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Yamamoto, N., Zhang, H. & Renschler, M. F., Sep 1 2013, In : Annals of Oncology. 24, 9, p. 2390-2396 7 p., mdt235.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Histology
Safety
Paclitaxel
80 Citations (Scopus)

Safety and efficacy of weekly nab ® -paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H. & Renschler, M. F., Feb 1 2013, In : Annals of Oncology. 24, 2, p. 314-321 8 p., mds461.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Safety
Disease-Free Survival
Paclitaxel
33 Citations (Scopus)

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

Tamiya, A., Okamoto, I., Miyazaki, M., Shimizu, S., Kitaichi, M. & Nakagawa, K., Jan 1 2013, In : Journal of Clinical Oncology. 31, 1

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Pyrazoles
Pyridines
X Ray Computed Tomography
Fatal Outcome
11 Citations (Scopus)

Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs

Ogi, S., Fujita, H., Kashihara, M., Yamamoto, C., Sonoda, K., Okamoto, I., Nakagawa, K., Ohdo, S., Tanaka, Y., Kuwano, M. & Ono, M., May 1 2013, In : Cancer Science. 104, 5, p. 573-583 11 p.

Research output: Contribution to journalArticle

Sorting Nexins
Epidermal Growth Factor Receptor
Membranes
Pharmaceutical Preparations
Lung Neoplasms
2012

[Molecular-targeted drug for non-small cell lung cancer].

Okamoto, I., Jan 1 2012, In : Unknown Journal. 70 Suppl 8, p. 438-442 5 p.

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Anilides
Molecular Targeted Therapy
Pyrimidines
Non-Small Cell Lung Carcinoma
98 Citations (Scopus)

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., Kaneda, H., Takezawa, K., Kuwata, K., Yamaguchi, H., Hatashita, E., Nishio, K. & Nakagawa, K., Nov 15 2012, In : Clinical Cancer Research. 18, 22, p. 6219-6226 8 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor
Protein-Tyrosine Kinases
Lung Neoplasms
Epidermal Growth Factor Receptor
12 Citations (Scopus)

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer

Sakai, K., Okamoto, I., Takezawa, K., Hirashima, T., Kaneda, H., Takeda, M., Matsumoto, K., Kimura, H., Fujita, Y., Nakagawa, K., Arao, T. & Nishio, K., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 5, p. 913-918 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Mass Spectrometry
Paraffin
Formaldehyde
Fluorescence In Situ Hybridization
58 Citations (Scopus)

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

Okamoto, W., Okamoto, I., Arao, T., Kuwata, K., Hatashita, E., Yamaguchi, H., Sakai, K., Yanagihara, K., Nishio, K. & Nakagawa, K., Jul 1 2012, In : Molecular Cancer Therapeutics. 11, 7, p. 1557-1564 8 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Stomach Neoplasms
X-Linked Inhibitor of Apoptosis Protein
Apoptosis
Inhibitor of Apoptosis Proteins
28 Citations (Scopus)

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment

Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., Kuwano, M., Ono, M. & Kage, M., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 1, p. 122-127 6 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Mutation
Antibodies

Capecitabine plus cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases

Kawakami, H., Nishina, S. I., Ueda, S., Kudo, T., Okamoto, W., Kurata, T., Okamoto, I. & Nakagawa, K., May 1 2012, In : Gastrointestinal Cancer Research. 5, 3, p. 103-105 3 p.

Research output: Contribution to journalArticle

Cisplatin
Stomach Neoplasms
Neoplasm Metastasis
Liver
Therapeutics
13 Citations (Scopus)

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC

Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A. & Nakagawa, K., Jun 1 2012, In : Japanese journal of clinical oncology. 42, 6, p. 528-533 6 p., hys042.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Mutation
Interstitial Lung Diseases
31 Citations (Scopus)

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

Takeda, M., Okamoto, I., Sakai, K., Kawakami, H., Nishio, K. & Nakagawa, K., Nov 1 2012, In : Annals of Oncology. 23, 11, p. 2931-2936 6 p., mds124.

Research output: Contribution to journalArticle

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Oncogene Fusion
11 Citations (Scopus)

Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement

Hayashi, H., Okamoto, I., Kimura, H., Sakai, K., Nishimura, Y., Nishio, K. & Nakagawa, K., Oct 2012, In : Anticancer Research. 32, 10, p. 4533-4538 6 p.

Research output: Contribution to journalArticle

erbB-1 Genes
Radiotherapy
Thorax
Non-Small Cell Lung Carcinoma
Mutation
10 Citations (Scopus)

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

Okamoto, I., Arao, T., Miyazaki, M., Satoh, T., Okamoto, K., Tsunoda, T., Nishio, K. & Nakagawa, K., Dec 1 2012, In : Cancer Science. 103, 12, p. 2135-2138 4 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor-2
Subunit Vaccines
Vaccines
Maximum Tolerated Dose
Neoplasms